Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-PSMA-101 in mCRPC and Salivary Gland Cancer
NCT04249947Phase 1Terminated
- Sponsor
- Poseida Therapeutics
- Start
- Feb 2020
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of P-PSMA-101 in metastatic castration-resistant prostate cancer (mCRPC) and salivary gland cancer (SGC) (4 arms), sponsored by Poseida Therapeutics. Primary endpoints: Assess the Safety of P-PSMA-101 at 15 years, Maximum Tolerated Dose at 28 days and 1 more. Started Feb 2020; status: terminated.
02
Drugs
P-PSMA-101
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT04249947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249947.